HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

ORY-1001: Overcoming the Differentiation Block in AML.

Abstract
In this issue of Cancer Cell, Maes and colleagues report in vitro and in vivo findings with ORY-1001-an oral, highly potent and selective covalent small-molecule inhibitor of lysine-specific demethylase 1 (LSD1)-in development for acute myeloid leukemia (AML), as well as correlative data from two AML patients receiving ORY-1001.
AuthorsPrithviraj Bose, Marina Y Konopleva
JournalCancer cell (Cancer Cell) Vol. 33 Issue 3 Pg. 342-343 (03 12 2018) ISSN: 1878-3686 [Electronic] United States
PMID29533778 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Comment)
CopyrightCopyright © 2018 Elsevier Inc. All rights reserved.
Chemical References
  • Histone Demethylases
Topics
  • Cell Differentiation
  • Histone Demethylases
  • Humans
  • Leukemia, Myeloid, Acute

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: